Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Magnetic Resonance Imaging | Research

Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

[18 F]-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has the ability to detect local and/or regional recurrence as well as distant metastasis. We aimed to evaluate the prognosis value of PET/CT in locoregional recurrent nasopharyngeal (lrNPC).

Methods

A total of 451 eligible patients diagnosed with recurrent I-IVA (rI-IVA) NPC between April 2009 and December 2015 were retrospectively included in this study. The differences in overall survival (OS) of lrNPC patients with and without PET/CT were compared in the I-II, III-IVA, r0-II, and rIII-IVA cohorts, which were grouped by initial staging and recurrent staging (according to MRI).

Results

In the III-IVA and rIII-IVA NPC patients, with PET/CT exhibited significantly higher OS rates in the univariate analysis (P = 0.045; P = 0.009; respectively). Multivariate analysis revealed that with PET/CT was an independent predictor of OS in the rIII-IVA cohort (hazard ratio [HR] = 0.476; 95% confidence interval [CI]: 0.267 to 0.847; P = 0.012). In the rIII-IVA NPC, patients receiving PET/CT sacns before salvage surgery had a better prognosis compared with MRI alone (P = 0.036). The recurrent stage (based on PET/CT) was an independent predictor of OS. (r0-II versus [vs]. rIII-IVA; HR = 0.376; 95% CI: 0.150 to 0.938; P = 0.036).

Conclusion

The present study showed that with PET/CT could improve overall survival for rIII-IVA NPC patients. PET/CT appears to be an effective method for assessing rTNM staging.
Appendix
Available only for authorised users
Literature
1.
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80.CrossRefPubMed
2.
Qiao H, Tan XR, Li H, Li JY, Chen XZ, Li YQ, Li WF, Tang LL, Zhou GQ, Zhang Y, et al. Association of Intratumoral Microbiota with prognosis in patients with nasopharyngeal carcinoma from 2 hospitals in China. JAMA Oncol. 2022;8(9):1301–9.CrossRefPubMedPubMedCentral
3.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
4.
Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, You R, Hua YJ, Sun Y, Ma J, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–95.CrossRefPubMed
5.
Lu T, Xu H, Huang W, Zong J, Pan C, Huang C, Xiao Y, Chen B, Li J, Pan J, et al. Constructing an individualized surveillance framework for nasopharyngeal carcinoma based on a dynamic risk-adapted approach. Radiother Oncol. 2023;185:109716.CrossRefPubMed
6.
Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P, et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019;79:101890.CrossRefPubMed
7.
Meng K, Tey J, Ho FCH, Asim H, Cheo T. Utility of magnetic resonance imaging in determining treatment response and local recurrence in nasopharyngeal carcinoma treated curatively. BMC Cancer. 2020;20(1):193.CrossRefPubMedPubMedCentral
8.
Lu ZJ, Liu T, Lin JY, Pei ST, Guo L, Liu SL, Mai HQ. Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma. Radiother Oncol. 2023;183:109635.CrossRefPubMed
9.
Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, Luo DH, Huang PY, Zhang X, Lin XP, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013;31(23):2861–9.CrossRefPubMed
10.
Qiu HZ, Zhang X, Liu SL, Sun XS, Mo YW, Lin HX, Lu ZJ, Guo J, Tang LQ, Mai HQ, et al. M1 stage subdivisions based on (18)F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma. Ther Adv Med Oncol. 2022;14:17588359221118785.CrossRefPubMedPubMedCentral
11.
Chen C, Xu T, Qiu X, Xie S, You Z, Hu Y, Zheng Y, Liang Z, Huang C, Chen T, et al. Selectively recommend (18)F-FDG PET/CT for patients with de novo nasopharyngeal carcinoma in endemic areas. Radiat Oncol. 2021;16(1):229.CrossRefPubMedPubMedCentral
12.
13.
Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, et al. Effect of Radiotherapy alone vs Radiotherapy with Concurrent Chemoradiotherapy on Survival without Disease Relapse in patients with low-risk nasopharyngeal carcinoma. A Randomized Clinical Trial. JAMA. 2022;328(8):728–36.CrossRefPubMedPubMedCentral
14.
Pan JJ, Ng WT, Zong JF, Chan LL, O’Sullivan B, Lin SJ, Sze HC, Chen YB, Choi HC, Guo QJ, et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(4):546–58.CrossRefPubMed
15.
Wei J, Pei S, Zhu X. Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: a meta-analysis. Oral Oncol. 2016;52:11–7.CrossRefPubMed
16.
Li Z, Li Y, Li N, Shen L. Positron emission tomography/computed tomography outperforms MRI in the diagnosis of local recurrence and residue of nasopharyngeal carcinoma: an update evidence from 44 studies. Cancer Med. 2019;8(1):67–79.CrossRefPubMed
17.
OuYang PY, Liu ZQ, Lin QG, He Y, Guo ZX, Yao WY, Xu SK, Peng QH, Xiao SM, Li J, et al. Benefit of [(18)F] FDG PET/CT in the diagnosis and salvage treatment of recurrent nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2023;50(3):881–91.CrossRefPubMed
18.
Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, Townsend DW, Berland LL, Parker JA, Hubner K, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47(5):885–95.PubMed
19.
Zhao Q, Dong A, Cui C, Ou Q, Ruan G, Zhou J, Tian L, Liu L, Ma H, Li H. MRI-Based metastatic nodal number and Associated Nomogram Improve Stratification of Nasopharyngeal Carcinoma patients: potential indications for individual induction chemotherapy. J Magn Reson Imaging. 2022.
20.
Huang L, Sim AYL, Wu Y, Liang Z, Li K, Du Y, Ong EHW, Tan HQ, Wee JTS, Xie Y, et al. Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. Ther Adv Med Oncol. 2020;12:1758835920970050.CrossRefPubMedPubMedCentral
21.
Huang Z, Tang S, Chen Z, Wang G, Shen H, Zhou Y, Wang H, Fan W, Liang D, Hu Y, et al. TG-Net: combining transformer and GAN for nasopharyngeal carcinoma tumor segmentation based on total-body uEXPLORER PET/CT scanner. Comput Biol Med. 2022;148:105869.CrossRefPubMed
22.
You R, Zou X, Wang SL, Jiang R, Tang LQ, Zhang WD, Li L, Zhang MX, Shen GP, Guo L, et al. New surgical staging system for patients with recurrent nasopharyngeal carcinoma based on the AJCC/UICC rTNM classification system. Eur J Cancer. 2015;51(13):1771–9.CrossRefPubMed
23.
Liu Q, Sun X, Li H, Zhou J, Gu Y, Zhao W, Li H, Yu H, Wang D. Types of Transnasal Endoscopic Nasopharyngectomy for recurrent nasopharyngeal carcinoma: Shanghai EENT Hospital Experience. Front Oncol. 2020;10:555862.CrossRefPubMed
24.
Li W, Liu Q, Xu H, Wang H, Zhang H, Liu Q, Wang J, Hu L, Li H, Sun X, et al. Innovative Fudan rT staging in endoscopic surgery for recurrent nasopharyngeal carcinoma. Head Neck. 2023;45(2):355–64.CrossRefPubMed
25.
Sun XS, Liang YJ, Jia GD, Liu SL, Liu LT, Guo SS, Sun R, Luo DH, Chen QY, Tang LQ, et al. Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinoma. Oral Oncol. 2020;106:104711.CrossRefPubMed
26.
Dongxiang W, Liting L, Yujing L, Meijuan L, Shanshan G, Longbin X, Yanzhou C, Meiling C, Kang N, Haiqiang M et al. Prediction of outcomes in patients with local recurrent nasopharyngeal carcinoma: development and validation of a four-factor prognostic model integrating baseline characteristics and [(18)F]FDG PET/CT parameters. Eur Radiol. 2022.
27.
Yan W, Sun C, Ou X, Hu C. Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy. Cancer Imaging. 2023;23(1):21.CrossRefPubMedPubMedCentral
28.
Lin HC, Chan SC, Cheng NM, Liao CT, Hsu CL, Wang HM, Lin CY, Chang JT, Ng SH, Yang LY, et al. Pretreatment (18)F-FDG PET/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2020;104:104628.CrossRefPubMed
29.
Alessi A, Lorenzoni A, Cavallo A, Padovano B, Iacovelli NA, Bossi P, Alfieri S, Serafini G, Colombo CB, Cicchetti A, et al. Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. Radiol Med. 2019;124(5):414–21.CrossRefPubMed
30.
Kulanthaivelu R, Kohan A, Hinzpeter R, Liu ZA, Hope A, Huang SH, Waldron J, O’Sullivan B, Ortega C, Metser U, et al. Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma. Front Oncol. 2022;12:952763.CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis
Publication date
01-12-2024
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12189-7

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Attitudes of oncology patients’ towards biospecimen donation for biobank research

Correction

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Research

Enrichment of colibactin-associated mutational signatures in unexplained colorectal polyposis patients

Research

Efficacy of salvage surgery versus re-irradiation for isolated regional lymph node recurrence in patients with nasopharyngeal carcinoma

Research

Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis

Research

Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits